References
1. Gerds AT, Gooley TA, Estey EH, Appelbaum FR, Deeg HJ, Scott BL.
Pretransplantation therapy with azacitidine vs induction chemotherapy
and posttransplantation outcome in patients with MDS. Biol Blood
Marrow Transplant . Aug 2012;18(8):1211-8.
doi:10.1016/j.bbmt.2012.01.009
2. Maher OM, Silva JG, Wu J, et al. Outcomes of children, adolescents,
and young adults following allogeneic stem cell transplantation for
secondary acute myeloid leukemia and myelodysplastic syndromes-The MD
Anderson Cancer Center experience. Pediatr Transplant . May
2017;21(3)doi:10.1111/petr.12890
3. Locatelli F, Strahm B. How I treat myelodysplastic syndromes of
childhood. Blood . Mar 29 2018;131(13):1406-1414.
doi:10.1182/blood-2017-09-765214
4. Nakano TA, Lau BW, Dickerson KE, et al. Diagnosis and treatment of
pediatric myelodysplastic syndromes: A survey of the North American
Pediatric Aplastic Anemia Consortium. Pediatr Blood Cancer . Oct
2020;67(10):e28652. doi:10.1002/pbc.28652
5. Strahm B, Nollke P, Zecca M, et al. Hematopoietic stem cell
transplantation for advanced myelodysplastic syndrome in children:
results of the EWOG-MDS 98 study. Leukemia . Mar
2011;25(3):455-62. doi:10.1038/leu.2010.297
6. Kobos R, Steinherz PG, Kernan NA, et al. Allogeneic hematopoietic
stem cell transplantation for pediatric patients with treatment-related
myelodysplastic syndrome or acute myelogenous leukemia. Biol Blood
Marrow Transplant . Mar 2012;18(3):473-80.
doi:10.1016/j.bbmt.2011.11.009
7. de Lima M, Giralt S, Thall PF, et al. Maintenance therapy with
low-dose azacitidine after allogeneic hematopoietic stem cell
transplantation for recurrent acute myelogenous leukemia or
myelodysplastic syndrome: a dose and schedule finding study.Cancer . Dec 1 2010;116(23):5420-31. doi:10.1002/cncr.25500
8. Pusic I, Choi J, Fiala MA, et al. Maintenance Therapy with Decitabine
after Allogeneic Stem Cell Transplantation for Acute Myelogenous
Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow
Transplant . Oct 2015;21(10):1761-9. doi:10.1016/j.bbmt.2015.05.026
9. Han S, Kim YJ, Lee J, et al. Model-based adaptive phase I trial
design of post-transplant decitabine maintenance in myelodysplastic
syndrome. J Hematol Oncol . Oct 23 2015;8:118.
doi:10.1186/s13045-015-0208-3
10. Oran B, de Lima M, Garcia-Manero G, et al. A phase 3 randomized
study of 5-azacitidine maintenance vs observation after transplant in
high-risk AML and MDS patients. Blood Adv . Nov 10
2020;4(21):5580-5588. doi:10.1182/bloodadvances.2020002544
11. Wei Y, Xiong X, Li X, et al. Low-dose decitabine plus venetoclax is
safe and effective as post-transplant maintenance therapy for high-risk
acute myeloid leukemia and myelodysplastic syndrome. Cancer Sci .
Sep 2021;112(9):3636-3644. doi:10.1111/cas.15048
12. DeFilipp Z, Chen YB. How I treat with maintenance therapy after
allogeneic HCT. Blood . Jan 5 2023;141(1):39-48.
doi:10.1182/blood.2021012412
13. Gozdzik J, Rewucka K, Krasowska-Kwiecien A, et al. Adoptive therapy
with donor lymphocyte infusion after allogenic hematopoietic SCT in
pediatric patients. Bone Marrow Transplant . Jan 2015;50(1):51-5.
doi:10.1038/bmt.2014.200
14. Schroeder T, Rautenberg C, Kruger W, et al. Treatment of relapsed
AML and MDS after allogeneic stem cell transplantation with decitabine
and DLI-a retrospective multicenter analysis on behalf of the German
Cooperative Transplant Study Group. Ann Hematol . Feb
2018;97(2):335-342. doi:10.1007/s00277-017-3185-5
15. Huschart E, Miller H, Salzberg D, et al. Azacitidine and
prophylactic donor lymphocyte infusions after hematopoietic stem cell
transplantation for pediatric high-risk acute myeloid leukemia.Pediatr Hematol Oncol . Mar 2021;38(2):154-160.
doi:10.1080/08880018.2020.1829220
16. Duncan CN, Majhail NS, Brazauskas R, et al. Long-Term Survival and
Late Effects among One-Year Survivors of Second Allogeneic Hematopoietic
Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic
Syndromes. Biology of Blood and Marrow Transplantation . Jan 01
2015;21(1):151-158. doi:10.1016/j.bbmt.2014.10.006
17. Yoshimi A, Mohamed M, Bierings M, et al. Second allogeneic
hematopoietic stem cell transplantation (HSCT) results in outcome
similar to that of first HSCT for patients with juvenile myelomonocytic
leukemia. Leukemia . Mar 2007;21(3):556-60.
doi:10.1038/sj.leu.2404537
18. Christopeit M, Kuss O, Finke J, et al. Second allograft for
hematologic relapse of acute leukemia after first allogeneic stem-cell
transplantation from related and unrelated donors: the role of donor
change. J Clin Oncol . Sep 10 2013;31(26):3259-71.
doi:10.1200/JCO.2012.44.7961
19. Orti G, Sanz J, Bermudez A, et al. Outcome of Second Allogeneic
Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies
following Allogeneic Hematopoietic Cell Transplantation: A Retrospective
Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.Biology of Blood and Marrow Transplantation . Mar
2016;22(3):584-588. doi:10.1016/j.bbmt.2015.11.012
20. Vrhovac R, Labopin M, Ciceri F, et al. Second reduced intensity
conditioning allogeneic transplant as a rescue strategy for acute
leukaemia patients who relapse after an initial RIC allogeneic
transplantation: analysis of risk factors and treatment outcomes. Apr 08
2019:1-8. doi:10.1038/bmt.2015.221
21. Ruutu T, de Wreede LC, van Biezen A, et al. Second allogeneic
transplantation for relapse of malignant disease: retrospective analysis
of outcome and predictive factors by the EBMT. Apr 08 2019:1-9.
doi:10.1038/bmt.2015.186
22. Mehta RS, Rezvani K. Can we make a better match or mismatch with KIR
genotyping? Hematology Am Soc Hematol Educ Program . Dec 2
2016;2016(1):106-118. doi:10.1182/asheducation-2016.1.106
23. Davies SM, Iannone R, Alonzo TA, et al. A Phase 2 Trial of
KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell
Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia:
Children’s Oncology Group AAML05P1 Study. Biol Blood Marrow
Transplant . Apr 2020;26(4):712-717. doi:10.1016/j.bbmt.2019.12.723
24. Mamcarz E, Madden R, Qudeimat A, et al. Improved survival rate in
T-cell depleted haploidentical hematopoietic cell transplantation over
the last 15 years at a single institution. Bone Marrow
Transplant . May 2020;55(5):929-938. doi:10.1038/s41409-019-0750-7
25. Debureaux PE, Labopin M, Mamez AC, et al. Fractionated gemtuzumab
ozogamicin in association with high dose chemotherapy: a bridge to
allogeneic stem cell transplantation in refractory and relapsed acute
myeloid leukemia. Bone Marrow Transplant . Feb 2020;55(2):452-460.
doi:10.1038/s41409-019-0690-2
26. Lane AA. Targeting CD123 in AML. Clin Lymphoma Myeloma Leuk .
Sep 2020;20 Suppl 1:S67-S68. doi:10.1016/S2152-2650(20)30466-3
27. Garcia JS, Flamand Y, Tomlinson BK, et al. Safety and Efficacy of
Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the
Post-BMT or Transplant Naïve Settings. Blood . 2020;136(Supplement
1):15-17. doi:10.1182/blood-2020-136235
28. Adema V, Kerr CM, Walter W, et al. Can Monosomy 7 be Targeted By
Next Generation Cereblon-Modulating Agents? Blood .
2019;134(Supplement_1):1270-1270. doi:10.1182/blood-2019-128967
29. Smith AR, Christiansen EC, Wagner JE, et al. Early hematopoietic
stem cell transplant is associated with favorable outcomes in children
with MDS. Pediatr Blood Cancer . Apr 2013;60(4):705-10.
doi:10.1002/pbc.24390
30. Winters AC, Maloney KW, Treece AL, Gore L, Franklin AK.
Single-center pediatric experience with venetoclax and azacitidine as
treatment for myelodysplastic syndrome and acute myeloid leukemia.Pediatr Blood Cancer . Oct 2020;67(10):e28398.
doi:10.1002/pbc.28398
31. Karol SE, Alexander TB, Budhraja A, et al. Venetoclax in combination
with cytarabine with or without idarubicin in children with relapsed or
refractory acute myeloid leukaemia: a phase 1, dose-escalation study.Lancet Oncol . Apr 2020;21(4):551-560.
doi:10.1016/S1470-2045(20)30060-7
32. Samra B, Konopleva M, Isidori A, Daver N, DiNardo C.
Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current
Evidence and Future Directions. Front Oncol . 2020;10:562558.
doi:10.3389/fonc.2020.562558
33. Place AE, Karol, S.E., Forlenza, C.J., Gambart M., Cooper T.M.,
Fraser C., Cario G., O’Brien M.M., Gerber N.U., Barnette P., Reinhardt
D., Ramsingh G., Tong B., Unnebrink K., Vishwamitra D., Dunbar F., Prine
B.A., Palenski T.A., Loh M.L. Pediatric Patients with
Relapsed/Refractory Acute Lymphoblastic Leukemia Harboring Heterogeneous
Genomic Profiles Respond to Venetoclax in Combination with Chemotherapy.
presented at: ASH ANNUAL MEETING & EXPOSITION; December 7, 2020 2020;
34. Ghoneim HE, Fan Y, Moustaki A, et al. De Novo Epigenetic Programs
Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation. Cell . Jun 29
2017;170(1):142-157 e19. doi:10.1016/j.cell.2017.06.007
35. Gao L, Zhang Y, Wang S, et al. Effect of rhG-CSF Combined With
Decitabine Prophylaxis on Relapse of Patients With High-Risk
MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized
Controlled Trial. J Clin Oncol . Dec 20 2020;38(36):4249-4259.
doi:10.1200/JCO.19.03277
36. Ma Y, Qu C, Dai H, et al. Maintenance therapy with decitabine after
allogeneic hematopoietic stem cell transplantation to prevent relapse of
high-risk acute myeloid leukemia. Bone Marrow Transplant . Jun
2020;55(6):1206-1208. doi:10.1038/s41409-019-0677-z
37. Xuan L, Liu Q. Maintenance therapy in acute myeloid leukemia after
allogeneic hematopoietic stem cell transplantation. J Hematol
Oncol . Jan 6 2021;14(1):4. doi:10.1186/s13045-020-01017-7
38. Wei Y, Xiong X, Li X, et al. Low-dose decitabine plus venetoclax is
safe and effective as post-transplant maintenance therapy for high-risk
acute myeloid leukemia and myelodysplastic syndrome. Cancer Sci .
Jun 29 2021;doi:10.1111/cas.15048